Topiramate as add-on therapy in non-respondent alcohol dependant patients: A 12 month follow-up study

Actas Espanolas de Psiquiatria

Volumn 35, Issue 4, 2007, Pages 236-242

  Fernandez Miranda J J ^a   Marina Gonzalez P A ^a   Montes Perez M ^a   Diaz Gonzalez T ^a   Gutierrez Cienfuegos E ^a   Antuna Diaz M J ^a   Bobes Garcia J ^b  

^a Servicio de Salud del Principado de Asturias (SESPA)   (Spain)

^b UNIVERSITY OF OVIEDO   (Spain)

Author keywords

ADIS; Alcohol dependence; Craving; Topiramate; Treatment

Indexed keywords

DRUG DERIVATIVE; DRUGS USED IN THE TREATMENT OF ADDICTION; FRUCTOSE; NEUROPROTECTIVE AGENT; TOPIRAMATE;

ADULT; ALCOHOLISM; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG POTENTIATION; FEMALE; FOLLOW UP; HUMAN; MALE; METABOLISM; MULTICENTER STUDY; PROSPECTIVE STUDY;

ADULT; ALCOHOL DETERRENTS; ALCOHOLISM; COHORT STUDIES; DOUBLE-BLIND METHOD; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; FRUCTOSE; HUMANS; MALE; NEUROPROTECTIVE AGENTS; PROSPECTIVE STUDIES;

EID: 34547237945     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Larimer ME, Palmer RS, Marlatt A. Relapse prevention. An overview of Marlatt's cognitive-behavioral model. Alcohol Res Health 1999;23:151-60.
2. Flannery B, Roberts A, Cooney N, Swift R, Anton R, Rohsenow D. The role of craving in alcohol use, dependence, and treatment. Alcohol Clin Exper Res 2001;21:299-308.
3. Anton RF. What is craving? Models and implications for treatment. Alcohol Res Health 1999;23:165-73.
4. Monti PM, Rohsenow DJ, Hutchison KE. Toward bridging the gap between biological, psychobiological and psychosocial models of alcohol craving. Addiction 2000;95(Suppl. 2): 229-36.
5. Litt M, Cooney N, Morse P. Research Report. Reactivity to alcohol-related stimuli in the laboratory and in the field: predictors of craving in treated alcoholics. Addiction 2000;95:889-900.
6. Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Rev 1993;18:247-91.
7. George M, Anton R, Bloomer C, Teneback C, Drobes D, Loberbaum J, et al. Activation of prefrontal cortex and anterior talamus in alcoholics subjects on exposure to alcohol. Specific cues. Arch Gen Psychiatry 2001;58:345-52.
8. Koob G, Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science 1997;278:52-8.
9. Johnson BA. Topiramate-induced neuromodulation of corticomesolimbic dopamine function: a new vista for the treatment of comorbid alcohol and nicotine dependence? Addict Behav 2004;29:1465-79.
10. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 2003;361:1677-85.
11. Rubio G, Ponce G, Jiménez-Arriero MA. Effects of topiramate in the treatment of alcohol dependence. Pharmacopsychiatry 2004;37:37-40.
12. Bobes J, Carreño JE, Gutiérrez CE. Estudio de la efectividad del control del craving con topiramato en pacientes con trastorno por dependencia de sustancias. Actas Esp Psiquiatr 2004;32:299-306.
13. Cheseaux M, Monnat M, Zullino DF. Topiramate in benzodiazepine withdrawal. Hum Psychopharmacol 2003;18:375-7.
14. Zullino DF, Cottier AC, Besson J. Topiramate in opiate withdrawal. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:1221-3.
15. Kampam KM, Pettinati H, Lynch KG, Dackis C, Sparkman T, Weigley C, O'Brien CP. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend 2004;75:233-40.
16. Rubio G, Urosa B, Santo-Domingo J. Validación de la Escala de la Intensidad de la Dependencia Alcohólica. Psiquiatr Biol 1998(Suppl. 1):44-7.
17. Komanduri R. Two cases of alcohol craving cured by topiramate. J Clin Psychiatry 2003;64:612.
18. Fleischhacker WW, Hummer M. Do phase III trials have clinical value? J Clin Psychopharmacol 1999;19:391-2.